Bagsværd, Denmark, 4 November 2022 – This doc discloses the information of the transaction(s) made in Novo Nordisk shares by the corporate’s board members, executives and their related individuals in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The firm’s board members, executives and their related individuals have given Novo Nordisk energy of legal professional on their behalf to publish buying and selling in Novo Nordisk shares by the corporate’s board members, executives and their related individuals.
Please discover beneath an announcement of such buying and selling in shares issued by Novo Nordisk.
| 1 | Details of the particular person discharging managerial obligations/particular person intently related | ||||
| a) | Name of the Board member/Executive/Associated Person | Novo Holdings A/S, Associated to Kasim Kutay | |||
| 2 | Reason for the notification | ||||
| a) | Position/standing | Member of the Board of Directors | |||
| b) | Initial notification/Amendment | Initial notification | |||
| 3 | Details of the issuer | ||||
| a) | Name | Novo Nordisk A/S | |||
| b) | LEI | 549300DAQ1CVT6CXN342 | |||
| 4 | Details of the transaction(s) | ||||
| a) | Description of the monetary instrument, sort of instrument, |
Shares | |||
| Identification code | Novo Nordisk B DK0060534915 | ||||
| b) | Nature of the transaction | Sale of shares | |||
| c) | Price(s) and quantity(s) | ||||
| Price(s) | Volume(s) | ||||
| DKK 851.26 | 4,207,500 shares | ||||
| d) | Aggregated info |
4,207,500 shares |
|||
| e) | Date of the transaction | 2022-11-04 | |||
| f) | Place of the transaction | Outside a buying and selling venue | |||
Novo Nordisk is a number one world healthcare firm, based in 1923 and headquartered in Denmark. Our objective is to drive change to defeat diabetes and different critical persistent ailments equivalent to weight problems and uncommon blood and endocrine problems. We achieve this by pioneering scientific breakthroughs, increasing entry to our medicines, and dealing to stop and in the end remedy illness. Novo Nordisk employs about 50,800 folks in 80 nations and markets its merchandise in round 170 nations. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For extra info, go to novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for additional info
Company announcement No 83 / 2022
- CA20221104_Insider Trading_Kasim Kutay
